A double-blind, randomized, placebo-controlled trial to evaluate the safety and efficacy of 12 weeks oral treatment with ACH126, 433 (b-L-Fd4C) [elvucitabine] in adults with lamivudine-resistant chronic hepatitis B

Trial Profile

A double-blind, randomized, placebo-controlled trial to evaluate the safety and efficacy of 12 weeks oral treatment with ACH126, 433 (b-L-Fd4C) [elvucitabine] in adults with lamivudine-resistant chronic hepatitis B

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Aug 2009

At a glance

  • Drugs Elvucitabine (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Aug 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 24 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top